Business Wire - July 2, 2002
As the HIV-1 virus is constantly mutating and evolving, it is important to continuously document these genetic variations in order to develop the next generation diagnostic tests that will still ensure results integrity despite these changes. Originally, molecular diagnostic tests were developed chiefly for the identification and monitoring of HIV-1 subtype B virus, the most common subtype of this virus found predominantly in Western Countries. Researchers, however, are now seeing a quantal shift in the virus where non-B viruses are actually dominant in certain populations, regardless of where a patient lives.
"We are in dire need of guarding against the effects of new non-B viruses and need to act now to preempt related problems. If we don't do so, HIV/AIDS patients' clinical outcomes, such as treatment efficacy and viral load and resistance testing, will be greatly compromised," commented Professor Clive Loveday, M.D., Ph.D., Charity Director of the International Clinical Virology Centre, and project leader of the SENTRY Study. "Roche Diagnostics is truly demonstrating their commitment to support clinical research in the field of HIV through the funding of this project. Using the Roche test, we have the ability to monitor in `real time' these emerging HIV-1 viruses and ultimately help assure patients that in the future, they will get the most accurate test to quantitate their virus, no matter which subtype of the virus they have," Dr. Loveday continued.
Six to eight hundred patient specimens obtained from the Royal Free Hospital in London and 40 other hospitals across the U.K. will be analyzed over the course of the next two years. According to Dr. Loveday, the U.K. has become a "melting pot" of HIV-1 viral subtypes and he is anticipating seeing very useful results from this patient population. Dr. Loveday will characterize the population that the SENTRY Study is investigating during a presentation at the upcoming XIV International AIDS Conference in Barcelona this July.
"With the globalization of the HIV epidemic, we're hopeful that the information obtained from this important scientific collaboration will result in our providing physicians, clinical laboratories and patients alike with the most advanced PCR tests that will perform well across all HIV-1 viral subtypes," said Heiner Dreismann, Ph.D., Head of Roche Molecular Diagnostics.
About the AMPLICOR HIV-1 MONITOR(R) Test, version 1.5
The AMPLICOR HIV-1 MONITOR Test, version 1.5, manufactured by Roche Diagnostics, provides sensitive measurements for the detection of the AIDS virus circulating in an infected person's blood ("viral load"). Equally as important, the test has the enhanced ability to quantitate HIV-1 Group M subtypes A-G of the virus. This includes HIV-1 non-B viruses.
Roche's AMPLICOR(R) products are based on the Company's PCR (polymerase chain reaction) technology. In June 1996 and March 1999, respectively, Roche received FDA approval for the AMPLICOR HIV-1 MONITOR(R) Test (measuring viral loads at levels as low as 400 HIV-1 RNA copies/mL) and the AMPLICOR HIV-1 MONITOR(R) UltraSensitive Method (measuring viral loads down to 50 HIV-1 RNA copies/mL).
About Roche and the Roche Diagnostics Division
Headquartered in Basel, Switzerland, Roche is one of the world's leading research-oriented healthcare groups in the fields of pharmaceuticals, diagnostics and vitamins. Roche's products and services address prevention, diagnosis and treatment of diseases, thus enhancing well-being and quality of life. Roche's Diagnostics Division, the world leader in in vitro diagnostics with a uniquely broad product portfolio, supplies a wide array of innovative testing products and services to researchers, physicians, patients, hospitals and laboratories world-wide. Roche Molecular Diagnostics, a business area of Roche Diagnostics, has made the polymerase chain reaction (PCR) the leading nucleic acid amplification technology (NAT) in the world. PCR technology allows minute amounts of genetic material to be amplified into billions of copies in just a few hours, thereby facilitating detection of the DNA or RNA of pathogenic organisms even before antibodies to these organisms are formed. Roche Diagnostics' website is located at www.roche-diagnostics.com.
CONTACT: Roche Paula Evangelista, 925/730-8374
SOURCE: Roche
020702
BW020704
Copyright © 2002 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2002. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2002. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .